1. H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice
- Author
-
Jaehyun Hwang, In-Young Jang, Eunseo Bae, Jaeseok Choi, Jeong Hwan Kim, Sang Beum Lee, Jong Hyun Kim, Jae Pil Lee, Ho Young Jang, Hyoung Tae Kim, Jong-Woo Lim, Minjoo Yeom, Eunhee Jang, Seong-Eun Kim, Hyoung Hwa Jeong, Jung Woo Kim, Seung-Yong Seong, Daesub Song, and Woonsung Na
- Subjects
Nanobody ,Influenza ,Pandemic 2009 flu ,Mice experiment ,Viral therapeutic ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Influenza A virus causes numerous deaths and infections worldwide annually. Therefore, we have considered nanobodies as a potential treatment for patients with severe cases of influenza. We developed a nanobody that was expected to have protective efficacy against the A/California/04/2009 (CA/04; pandemic 2009 flu strain) and evaluated its therapeutic efficacy against CA/04 in mice experiments. This nanobody was derived from the immunization of the alpaca, and the inactivated CA/04 virus was used as an immunogen. We successfully generated a nanobody library through bio-panning, phage ELISA, and Bio-layer interferometry. Moreover, we confirmed that administering nanobodies after lethal doses of CA/04 reduced viral replication in the lungs and influenza-induced clinical signs in mice. These research findings will help to develop nanobodies as viral therapeutics for CA/04 and other infectious viruses.
- Published
- 2024
- Full Text
- View/download PDF